AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18444145
Drug: Tomato products
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato products (no soy) for Weeks 0 through 4, targeting a minimum of 25 mg of lycopene/day
Trial: 18444145
Drug: Soy (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy (no tomatoes) for Weeks 0 through 4, providing 40 g of soy protein/day
Trial: 18444145
Drug: Combined tomato-rich
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined tomato-rich diet and soy supplements for Weeks 4 through 8
Trial: 10561342
Drug: Twice-daily thoracic
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily thoracic irradiation (TDTI)
Trial: 10561342
Drug: Once-daily thoracic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily thoracic irradiation (ODTI)
Trial: 1928770
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural anesthesia in combination with light general anesthesia (group 2)
Trial: 27152849
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behaviour therapy (CBT) guided by a clinician for 8 weeks, comprising 8 modules of written text.
Trial: 10073079
Drug: Hartmann's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hartmann's solution preloading (500 ml)
Trial: 7727602
Drug: Erythropoietin 200
RxNorm normalized name: ERYTHROPOIETIN 2000 UNT/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin 200 IU/kg/day with ferric pyrophosphate 40 mg/day intravenously for 7 days before and 14 days after operation
Trial: 7727602
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate 40 mg/day alone (control group)
Trial: 2024581
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy and postoperative radiotherapy
Trial: 7238993
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cleansing agent)
Trial: 26512604
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.125% ropivacaine + 0.3 μg/mL sufentanil
Trial: 10052485
Drug: Trandolapril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (4 mg)
Trial: 17566313
Drug: Verapamil-SR (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil-SR (240 mg)
Trial: 17566313
Drug: Trandolapril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (4 mg) + Verapamil-SR (240 mg) combination
Trial: 12911367
Drug: Diazepam 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 0.1 mg.kg‐1
Trial: 12911367
Drug: Diazepam (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (various doses: 0, 0.025, 0.5, 0.1, 0.175 mg.kg‐1)
Trial: 12911367
Drug: Diazepam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.1 mg.kg‐1)
Trial: 12911367
Drug: Lower diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower diazepam doses
Trial: 12911367
Drug: Higher diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher diazepam doses
Trial: 11138599
Drug: Conventional NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional NSAIDs (diclofenac, ibuprofen, naproxen)
Trial: 8815995
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment (A) consisting of postural training, manual technique, and psychological support
Trial: 8815995
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (B) using physical agents only (electrical and sonic modalities)
Trial: 1357553
Drug: Corticosteroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid group (beclomethasone, 800 micrograms daily)
Trial: 1357553
Drug: Anticholinergic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic group (ipratropium bromide, 160 micrograms daily)
Trial: 4074611
Drug: Ultrasound administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound administration
Trial: 2887192
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 25 mg day‐1)
Trial: 2887192
Drug: Pindolol (PIND,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (PIND, 10 mg day‐1)
Trial: 2887192
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HCTZ and PIND
Trial: 29906734
Drug: Fully weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully weight-based dosing of chemotherapy (LV5FU2)
Trial: 29906734
Drug: Dose-reduced chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-reduced chemotherapy
Trial: 21119149
Drug: Regular recommendation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular recommendation role (antidepressant for depression, depot for schizophrenia)
Trial: 21119149
Drug: Self role
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self role (treatment chosen for themselves)
Trial: 18830096
Drug: Iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 400 (90 mL)
Trial: 18830096
Drug: Iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 300 (120 mL)
Trial: 17015530
Drug: Synchronized intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronized intermittent mandatory ventilation plus pressure support (700-1000 g birth weight strata)
Trial: 1814841
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg
Trial: 1814841
Drug: Ofloxacin 400
RxNorm normalized name: ofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 400 mg
Trial: 6383998
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous administration of vasopressin
Trial: 6383998
Drug: Complications of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complications of treatment mortality
Trial: 25091714
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100,000-U bolus intramuscularly plus 50,000 U orally weekly)
Trial: 20522283
Drug: Circumferential casting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circumferential casting (CC)
Trial: 20522283
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (CC, VDS, MST)
Trial: 11876600
Drug: Immunotherapy (IT)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (IT) with pullulan‐conjugated antigen (CS‐560)
Trial: 10992846
Drug: Deep topical
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep topical fornix nerve block anaesthesia (DTFNBA)
Trial: 9001651
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (ACV) 5‐80 mg/kg daily in four divided doses
Trial: 1483856
Drug: Vigabatrin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (2 g/day)
Trial: 1483856
Drug: Vigabatrin (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (dose titration up to 4 g/day)
Trial: 4006263
Drug: Topical phenylpropanolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical phenylpropanolamine (PPA) 25 mg/ml
Trial: 27576846
Drug: HDM2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HDM2 inhibitor SAR405838
Trial: 25065489
Drug: Buprenorphine pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine pharmacotherapy and behavioral treatment
Trial: 17957000
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrM) supplementation (loading phase, 20 g/day x 3 days; maintenance phase, 5 g/day x 7 days)
Trial: 7731108
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (r‐hGH) at a dose of 0.5 IU/kg/week
Trial: 7731108
Drug: recombinant growth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant growth hormone (r‐hGH) at a dose of 1.0 IU/kg/week
Trial: 3076118
Drug: Gemfibrozil 600mg
RxNorm normalized name: GEMFIBROZIL 600MG TAB
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600mg twice daily
Trial: 24916951
Drug: 3-month exercise
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month exercise intervention (160 min/week of moderate intensity aerobic walking, twice weekly resistance training with resistance bands, and six discussion groups)
Trial: 24370303
Drug: Tetrandrine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrandrine (100 mg) twice a day + Acetylcysteine effervescent tablets (600 mg) twice a day
Trial: 24370303
Drug: Routine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine therapy (anti-inflammatory, antitussive, and antiasthmatic drugs)
Trial: 21385365
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy plus standard wound care
Trial: 16815864
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with celecoxib 200 mg once daily
Trial: 16815864
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with celecoxib 200 mg once daily
Trial: 2682474
Drug: Naloxone 4
RxNorm normalized name: naloxone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 4 mg i.v.
Trial: 334219
Drug: Nomifensine 75
RxNorm normalized name: nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nomifensine 75 mg
Trial: 11193231
Drug: Desipramine 50
RxNorm normalized name: desipramine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desipramine 50 mg
Trial: 31160472
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (topical numbing cream, positioning, distraction by a specialized pain nurse)
Trial: 27445468
Drug: UMEC 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC 62.5 µg
Trial: 27445468
Drug: VI 25
RxNorm normalized name: VITRAKVI 25mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VI 25 µg
Trial: 22723325
Drug: Roflumilast 500
RxNorm normalized name: ROFLUMILAST 500MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 500 μg once daily
Trial: 22572567
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel used topically twice daily for 2 weeks
Trial: 22572567
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole cream used topically twice daily for 2 weeks
Trial: 19235039
Drug: Broccoli intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broccoli intake (200 g)
Trial: 15485530
Drug: CO(2) laser
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO(2) laser treatment
Trial: 15485530
Drug: Glucantime treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime treatment
Trial: 7988089
Drug: Aspirin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (30 to 283 mg)
Trial: 2511610
Drug: Pirbuterol 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirbuterol 20 mg thrice daily for 6 months
Trial: 31351491
Drug: Oral cotrimoxazole
RxNorm normalized name: clotrimazole Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cotrimoxazole
Trial: 31351491
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (dry mopping and ciprofloxacin drops) plus dilute povidone-iodine ear wash
Trial: 31351491
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (dry mopping and ciprofloxacin drops) plus placebo
Trial: 24120480
Drug: Perioperative FOLFOX4
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative FOLFOX4 chemotherapy (6 cycles of oxaliplatin 85mg/m², folinic acid 200 mg/m² or 100 mg/m², fluorouracil 400 mg/m² bolus and 600 mg/m² continuous infusion)
Trial: 24120480
Drug: Perioperative FOLFOX4
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative FOLFOX4 chemotherapy
Trial: 21145193
Drug: Group MgSO(4)
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group MgSO(4) - 50mg of magnesium sulphate 5% (1.0 mL) added to 25 μg of fentanyl citrate (0.5 mL) and 300 μg of morphine
Trial: 21145193
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group S - 25 μg of fentanyl citrate (0.5 mL) + 300 μg of morphine + 1.0 mL of preservative-free 0.9% sodium chloride
Trial: 18287358
Drug: CLA-rich fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLA-rich fat (115 g/d, 5.5 g/d CLA oil, 39.4% cis9, trans11 and 38.5% trans10, cis12)
Trial: 12543892
Drug: Normal haemoglobin
RxNorm normalized name: Abnormal haemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal haemoglobin (135-160 g/l)
Trial: 12543892
Drug: Subnormal haemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subnormal haemoglobin (90-120 g/l)
Trial: 10987585
Drug: Eptifibatide (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eptifibatide (180 microg/kg bolus + continuous infusion of 2.0 microg/kg/min for ≤96 h)
Trial: 8011251
Drug: Potentially antitoxoplasmic
RxNorm normalized name: Potentilla discolor whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentially antitoxoplasmic drugs (trimethoprim‐sulphamethoxazole, pyrimethamine, dapsone, pyrimethamine‐sulphadoxine, sulphadiazine)
Trial: 2891797
Drug: VEPA or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEPA or VEPA-M therapy
Trial: 26600459
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with ART for 12 months
Trial: 12691976
Drug: Evidence-based medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based medicine (EBM) curriculum workshop series (ten sessions) introduced in 2000
Trial: 10871576
Drug: 0.7 g
RxNorm normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7 g protein/kg
Trial: 10871576
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g protein/kg
Trial: 10871576
Drug: 0.9 g
RxNorm normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 g protein/kg
Trial: 10871576
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g protein/kg
Trial: 8256784
Drug: Live oral
RxNorm normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live oral cholera vaccine CVD 103‐HgR (5 x 10(8) colony forming units)
Trial: 3572463
Drug: Intensive consolidation
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive consolidation chemotherapy (four courses)
Trial: 23752057
Drug: 18 mcg
RxNorm normalized name: Spiriva, 18 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg tiotropium
Trial: 23752057
Drug: 18 mcg
RxNorm normalized name: Spiriva, 18 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mcg tiotropium plus 12 mcg formoterol
Trial: 22735462
Drug: Sugammadex 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 32 mg/kg
Trial: 20825252
Drug: Sugammadex 64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 64 mg/kg
Trial: 20825252
Drug: Sugammadex 96
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex 96 mg/kg
Trial: 16010547
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 2 ml of sterile saline into the pack prior to opening
Trial: 16010547
Drug: No injection
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No injection of saline into the pack prior to opening
Trial: 1678392
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (100, 200, 500, 1000 micrograms)
Trial: 24346811
Drug: Extended-release paliperidone
RxNorm normalized name: paliperidone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release paliperidone (paliperidone ER) 6 mg
Trial: 24346811
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone (mean dose: 4.0 mg)
Trial: 24346811
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from oral risperidone to paliperidone ER
Trial: 21121492
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behavioral therapy (CBT) intervention program, conducted over four consecutive 1.5-hour weekly sessions.
Trial: 12006131
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/day
Trial: 7751526
Drug: Antihistamine and
RxNorm normalized name: Antihistamine and Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine and anti-inflammatory medicines timed to the day-night temporal pattern in symptom manifestation and intensity.
Trial: 7751526
Drug: Traditional equal-interval,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional equal-interval, equal-dose medication schedules.
Trial: 401194
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg bolus of methylprednisolone
Trial: 401194
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg bolus of methylprednisolone
Trial: 24331203
Drug: Medication Adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Adherence (MA)
Trial: 11739353
Drug: Traditional bonesetters
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional bonesetters (TBS) treatment
Trial: 11739353
Drug: Orthodox treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodox treatment in hospital
Trial: 28591764
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein supplement (W)
Trial: 25399618
Drug: New combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New combination of retinoids and depigmenting agents
Trial: 20354468
Drug: Psychomotor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor therapy (home program and 3 outpatient sessions)
Trial: 20354468
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (home program focusing on pain contingent training of back, abdominal, and leg muscle functional strength and endurance, stretching, and cardiovascular fitness)
Trial: 20354468
Drug: Psychomotor therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychomotor therapy
Trial: 18845961
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 1440 UI of hepatitis A vaccine (HAVRIX) at weeks 0, 4, and 24
Trial: 18845961
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of hepatitis A vaccine 24 weeks apart
Trial: 14642682
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg/day)